Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “underperform” rating reissued by research analysts at Wells Fargo & Company in a research note issued on Thursday. They currently have a $9.00 target price on the specialty pharmaceutical company’s stock. Wells Fargo & Company’s price target indicates a potential downside of 36.03% from the company’s current price.

Several other research firms have also recently weighed in on VRX. J P Morgan Chase & Co restated a “hold” rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, May 9th. Zacks Investment Research cut Valeant Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 13th. BidaskClub upgraded Valeant Pharmaceuticals International from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. TD Securities cut their target price on Valeant Pharmaceuticals International from $18.50 to $15.00 and set a “hold” rating for the company in a research note on Wednesday, May 10th. Finally, Deutsche Bank AG set a $19.00 target price on Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research note on Monday, July 17th. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $17.26.

Valeant Pharmaceuticals International (VRX) opened at 14.07 on Thursday. The company’s 50 day moving average price is $16.44 and its 200 day moving average price is $13.39. The company’s market cap is $4.90 billion. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $32.74.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. The firm had revenue of $2.23 billion during the quarter, compared to analysts’ expectations of $2.23 billion. During the same period in the prior year, the company earned ($0.88) earnings per share. The company’s quarterly revenue was down 7.7% on a year-over-year basis. Equities research analysts anticipate that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Stock Rating Reaffirmed by Wells Fargo & Company” was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/10/valeant-pharmaceuticals-international-inc-nysevrx-stock-rating-reaffirmed-by-wells-fargo-company.html.

Hedge funds have recently modified their holdings of the company. Intact Investment Management Inc. increased its stake in shares of Valeant Pharmaceuticals International by 3.2% in the second quarter. Intact Investment Management Inc. now owns 156,100 shares of the specialty pharmaceutical company’s stock worth $3,501,000 after buying an additional 4,900 shares during the last quarter. Key Square Capital Management LLC acquired a new stake in shares of Valeant Pharmaceuticals International during the second quarter worth $16,396,000. Partners Value Investments LP increased its stake in shares of Valeant Pharmaceuticals International by 35.5% in the second quarter. Partners Value Investments LP now owns 527,100 shares of the specialty pharmaceutical company’s stock worth $9,119,000 after buying an additional 138,000 shares during the last quarter. Commerzbank Aktiengesellschaft FI increased its stake in shares of Valeant Pharmaceuticals International by 144.9% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 440,873 shares of the specialty pharmaceutical company’s stock worth $7,627,000 after buying an additional 260,881 shares during the last quarter. Finally, Cannell Peter B & Co. Inc. acquired a new stake in shares of Valeant Pharmaceuticals International during the second quarter worth $20,981,000. Hedge funds and other institutional investors own 51.14% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.